420 related articles for article (PubMed ID: 18691179)
41. Intravesical epirubicin treatment following TUR in superficial bladder tumours.
Imamoğlu MA; Bakirtaş H; Yiğitbaşi O; Ersoy H; Sertçelik AN
Arch Esp Urol; 2001 Dec; 54(10):1147-53. PubMed ID: 11852530
[TBL] [Abstract][Full Text] [Related]
42. [Prophylactic effect of UFT in combination with intravesical chemotherapy on the recurrence of superficial bladder tumor].
Yoshida O; Kakehi Y; Nishio Y; Tomoyoshi T; Konami T; Usui T; Igawa M; Takenaka I; Fujita K
Hinyokika Kiyo; 1992 Dec; 38(12):1437-43. PubMed ID: 1288238
[TBL] [Abstract][Full Text] [Related]
43. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL
Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640
[TBL] [Abstract][Full Text] [Related]
45. Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
Wu WJ; Ke HL; Yang YH; Li CC; Chou YH; Huang CH
J Urol; 2010 Jan; 183(1):56-61. PubMed ID: 19913833
[TBL] [Abstract][Full Text] [Related]
46. Chemo-prevention in superficial bladder cancer using mitomycin C: a survey of the practice patterns of British urologists.
Clarke NS; Basu S; Prescott S; Puri R
BJU Int; 2006 Apr; 97(4):716-9. PubMed ID: 16536760
[TBL] [Abstract][Full Text] [Related]
47. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence.
Giannopoulos A; Constantinides C; Fokaeas E; Stravodimos C; Giannopoulou M; Kyroudi A; Gounaris A
Clin Cancer Res; 2003 Nov; 9(15):5550-8. PubMed ID: 14654535
[TBL] [Abstract][Full Text] [Related]
48. [Long-term results of intravesical N-CWS instillation to prevent recurrence after surgery for bladder cancer].
Chen S; Lin Z; Xu E
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):228-30. PubMed ID: 10920905
[TBL] [Abstract][Full Text] [Related]
49. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Hendricksen K; Witjes WP; Idema JG; Kums JJ; van Vierssen Trip OB; de Bruin MJ; Vergunst H; Caris CT; Janzing-Pastors MH; Witjes JA
Eur Urol; 2008 May; 53(5):984-91. PubMed ID: 18248876
[TBL] [Abstract][Full Text] [Related]
50. Intravesical mitomycin C for superficial transitional cell carcinoma.
Bolenz C; Cao Y; Arancibia MF; Trojan L; Alken P; Michel MS
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1273-82. PubMed ID: 16925493
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant intravesical treatment with a standardized mistletoe extract to prevent recurrence of superficial urinary bladder cancer.
Elsässer-Beile U; Leiber C; Wetterauer U; Bühler P; Wolf P; Lucht M; Mengs U
Anticancer Res; 2005; 25(6C):4733-6. PubMed ID: 16334168
[TBL] [Abstract][Full Text] [Related]
52. Impact of age on outcomes of patients with non-muscle-invasive bladder cancer treated with immediate postoperative instillation of mitomycin C.
Xylinas E; Kent M; Dabi Y; Rieken M; Kluth LA; Al Hussein Al Awamlh B; Ouzaid I; Pycha A; Comploj E; Svatek RS; Lotan Y; Karakiewicz PI; Holmang S; Shariat SF
Urol Oncol; 2018 Mar; 36(3):89.e1-89.e5. PubMed ID: 29221642
[TBL] [Abstract][Full Text] [Related]
53. The MRC superficial bladder cancer trial of intravesical mytomicin-c after complete surgical resection. Sequential statistical methods applied to survival data from a randomised clinical trial.
Donaldson AM; Gonzalez JG; Parmar MK; Donaldson N
Int J Surg; 2009 Oct; 7(5):441-5. PubMed ID: 19486950
[TBL] [Abstract][Full Text] [Related]
54. [Postoperative intravesical installation of tetrahydropyranyl-adriamycin (THP) and cytosine arabinoside (CA) for superficial bladder cancer: clinical results of prophylactic effects on recurrence].
Hashimoto H; Yachiku S; Watabe Y; Niibori D; Yamauchi K; Osanai H; Ohashi K; Wakabayashi A; Fujisawa M
Gan To Kagaku Ryoho; 1994 May; 21(6):833-8. PubMed ID: 8185341
[TBL] [Abstract][Full Text] [Related]
55. Immediate intravesical instillation of mitomycin C after transurethral resection of bladder tumor in patients with low-risk superficial transitional cell carcinoma of bladder.
Barghi MR; Rahmani MR; Hosseini Moghaddam SM; Jahanbin M
Urol J; 2006; 3(4):220-4. PubMed ID: 17559045
[TBL] [Abstract][Full Text] [Related]
56. Continuous saline bladder irrigation after transurethral resection is a prophylactic treatment choice for non-muscle invasive bladder tumor.
Onishi T; Sasaki T; Hoshina A; Yabana T
Anticancer Res; 2011 Apr; 31(4):1471-4. PubMed ID: 21508405
[TBL] [Abstract][Full Text] [Related]
57. [Intravesial instillation of recombination interferon-alpha and pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer].
Deng JH; Bai JL; Zhang SS; Ma PC; Wan JH
Ai Zheng; 2004 Jul; 23(7):839-41. PubMed ID: 15248924
[TBL] [Abstract][Full Text] [Related]
58. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
59. Endovesical instillation of mitomycin-C in preventing recurrence of superficial bladder carcinoma.
Wu JJ; Yin ZL; Zhu JN
Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1160-3. PubMed ID: 1514829
[TBL] [Abstract][Full Text] [Related]
60. Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer.
Gårdmark T; Jahnson S; Wahlquist R; Wijkström H; Malmström PU
BJU Int; 2007 Apr; 99(4):817-20. PubMed ID: 17244282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
